NeoGenomics, Inc. (NASDAQ:NEO) Stock Holdings Reduced by Choreo LLC

Choreo LLC reduced its stake in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 60.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 39,971 shares of the medical research company's stock after selling 61,978 shares during the period. Choreo LLC's holdings in NeoGenomics were worth $379,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. CWM LLC boosted its holdings in NeoGenomics by 42.6% in the first quarter. CWM LLC now owns 6,299 shares of the medical research company's stock valued at $60,000 after purchasing an additional 1,883 shares in the last quarter. Sterling Capital Management LLC boosted its holdings in NeoGenomics by 788.7% in the fourth quarter. Sterling Capital Management LLC now owns 3,706 shares of the medical research company's stock valued at $61,000 after purchasing an additional 3,289 shares in the last quarter. Teacher Retirement System of Texas acquired a new position in NeoGenomics in the first quarter valued at approximately $178,000. Sherbrooke Park Advisers LLC acquired a new position in NeoGenomics in the fourth quarter valued at approximately $183,000. Finally, Bailard Inc. acquired a new position in NeoGenomics in the first quarter valued at approximately $183,000. 98.50% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at NeoGenomics

In other NeoGenomics news, Director Lynn A. Tetrault purchased 7,000 shares of the stock in a transaction dated Friday, May 9th. The shares were acquired at an average price of $8.14 per share, for a total transaction of $56,980.00. Following the completion of the acquisition, the director owned 7,000 shares of the company's stock, valued at $56,980. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Stephen M. Kanovsky purchased 4,000 shares of the stock in a transaction dated Wednesday, May 7th. The shares were acquired at an average price of $7.78 per share, for a total transaction of $31,120.00. Following the acquisition, the director directly owned 40,090 shares of the company's stock, valued at $311,900.20. This represents a 11.08% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 50,600 shares of company stock valued at $400,238 over the last ninety days. Company insiders own 2.40% of the company's stock.

NeoGenomics Price Performance

Shares of NEO traded up $0.23 during midday trading on Friday, reaching $5.07. The stock had a trading volume of 1,608,153 shares, compared to its average volume of 1,924,710. The firm's 50 day moving average price is $7.03 and its 200-day moving average price is $9.37. The company has a market capitalization of $654.30 million, a P/E ratio of -6.25 and a beta of 1.63. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.92 and a quick ratio of 1.95. NeoGenomics, Inc. has a 52 week low of $4.72 and a 52 week high of $19.11.

NeoGenomics (NASDAQ:NEO - Get Free Report) last announced its earnings results on Tuesday, April 29th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.06). The company had revenue of $168.04 million for the quarter, compared to analyst estimates of $171.38 million. NeoGenomics had a negative return on equity of 2.72% and a negative net margin of 15.10%. The firm's revenue for the quarter was up 7.6% on a year-over-year basis. During the same period last year, the firm earned ($0.02) earnings per share. On average, analysts forecast that NeoGenomics, Inc. will post -0.2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on NEO shares. The Goldman Sachs Group decreased their price objective on NeoGenomics from $15.00 to $10.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. Leerink Partnrs cut NeoGenomics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. Morgan Stanley set a $8.00 price objective on NeoGenomics and gave the stock an "equal weight" rating in a research report on Wednesday. William Blair restated a "market perform" rating on shares of NeoGenomics in a research report on Tuesday. Finally, BTIG Research restated a "neutral" rating on shares of NeoGenomics in a research report on Wednesday. Nine investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $12.88.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.